Kane Biotech, a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, has developed and patented a new bone tissue regenerating fusion peptide based on the company's competence stimulating peptide (CSP) oral care technology.
This new patent covers the invention of a unique combination product using the company's CSP technology to help grow bone cells by enhancing bone cell binding and bone tissue regeneration.
The invention can be used for the following:
- Osteogenic cell binding for repairing the dental bone defects such as those caused by bone loss resulting from moderate to severe periodontitis
- Filling tooth extraction sites or sinus elevation grafting
- Treatment of fractures
- Using as a filler in bone
- Prevention of decrease in the bone substance related to osteoporosis
- Prevention of fractures associated with osteoporosis and rheumatoid arthritis
The global market for bone tissue regeneration is more than $32 billion a year. This includes dental bone grafts, osteoporosis, osteoarthritis, and rheumatoid arthritis. The dental bone graft global market alone is estimated at $266 million per year.
"This exciting new invention gives us the opportunity to discuss our technology platforms in a new global market as we continue to focus our near-term resources and attention on DispersinB," stated Gord Froehlich, president and CEO of Kane Biotech, in a press release. "In addition to antimicrobial activity against dental cavity and periodontal diseases associated bacteria, we are excited to learn our CSP-based technology has potential to be used in combination with bone tissue regenerating products for the treatment of diseases and defects related to bone loss and bone regeneration."
